Non-Small Cell Lung Cancer Drugs Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, China, Canada, UK - Size and Forecast 2024-2028

Non-Small Cell Lung Cancer Drugs Market Size 2024-2028 

The non-small cell lung cancer (NSCLC)drugs market size is forecast to increase by USD 21.06 billion at a CAGR of 10.87% between 2023 and 2028.

• The non-small cell lung cancer (NSCLC) drug market is experiencing significant growth due to several factors. The increasing prevalence of NSCLC, driven by air pollution and smoking behaviors, is a major market driver. Additionally, the approval and introduction of combination therapies, such as those involving HER2-positive gastric and gastroesophageal (GEJ) adenocarcinoma medications, are contributing to market expansion.
• However, the high cost of NSCLC treatment poses a challenge to market growth. Daiichi Sankyo and other pharmaceutical companies are focusing on developing new treatments, including Fruquintinib (HMPL-013) and PD-L1 antibody therapies, to address this need and meet the demands of the growing patient population.

What will be the Non-Small Cell Lung Cancer Drugs Market Size  During the Forecast Period?

 Request Free Sample

• Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related deaths worldwide. The NSCLC drugs market encompasses various treatment modalities, including small molecules, biologics, alkylating agents, antimetabolites, mitotic inhibitors, multi-kinase inhibitors, chemotherapy, radiation therapy, targeted therapy, and immunotherapy. The NSCLC drugs market has seen significant advancements in recent years, driven by the development of innovative treatment options. Small molecules and biologics have been the primary focus of research and development (R&D) efforts due to their targeted approach and improved efficacy. The pipeline for NSCLC drugs is strong, with several promising candidates in various stages of clinical development. One such candidate is Fruquintinib (HMPL-013), a small molecule inhibitor of vascular endothelial growth factor receptor (VEGFR) 1-3, which is currently under investigation for the treatment of advanced NSCLC. Another promising development is the use of PD-L1 antibodies in immunotherapy, which has shown promising results in clinical trials.
• The diagnosis and treatment of NSCLC involve various modalities, including CT scans and radiation therapy. Radiation oncologists play a crucial role in the management of NSCLC patients, using advanced technologies such as deep learning systems to optimize radiation therapy plans. The risk factors for NSCLC include a history of smoking, exposure to air pollution, and occupational hazards such as asbestos and arsenic. The availability and accessibility of these drugs depend on various factors, including insurance coverage, geographic location, and patient demographics. The NSCLC drugs market is expected to continue growing due to the increasing prevalence of the disease and the development of new and innovative treatment options. The use of advanced technologies such as deep learning systems and targeted therapies is expected to drive the growth of the market in the coming years.

How is this market segmented and which is the largest segment?

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

• Type
  • Adenocarcinoma
  • Squamous cell carcinoma
  • Large cell carcinoma
• Product
  • Biologics
  • Small molecule targeted therapy
  • Chemotherapy
• Geography
  • North America
    • Canada
    • US
  • Europe
    • Germany
    • UK
  • Asia
    • China
  • Rest of World (ROW)

By Type Insights

• The adenocarcinoma segment is estimated to witness significant growth during the forecast period.

Adenocarcinoma is a type of cancer that develops in the glandular tissue, which produces and secretes substances into the body. This form of cancer affects various organs, including the breast, lungs, esophagus, stomach, colon, rectum, pancreas, prostate, and uterus. Several factors contribute to the development of adenocarcinoma. Smoking is a significant risk factor for adenocarcinoma, making it a leading cause of this disease. Exposure to toxins in the home or work environment can also contribute to its development. Previous radiation therapy is another risk factor, increasing the likelihood of adenocarcinoma. In Massachusetts, researchers are developing innovative solutions to combat adenocarcinoma.

For instance, a deep learning system has been designed to analyze CT scans and assist radiation oncologists in diagnosing and treating the disease more accurately. Additionally, companies like Moderna and Rain Therapeutics are exploring the use of messenger RNA (mRNA) and anti-TIM-3 antibody, respectively, for targeted therapy. These advancements in technology and pharmaceuticals offer hope for improving life expectancy for patients diagnosed with adenocarcinoma. By continuing to invest in research and development, we can make significant strides in the fight against this disease.

Get a glance at the market report of share of various segments Request Free Sample

The adenocarcinoma segment was valued at USD 8.75 billion in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

• North America is estimated to contribute 38% to the growth of the global market during the forecast period.

Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market share of various regions Request Free Sample

In North America, the market for drugs used to treat Non-Small Cell Lung Cancer (NSCLC) is experiencing significant growth due to the increasing incidence of this disease and the presence of major pharmaceutical companies. The region's market leadership can be attributed to the high prevalence of NSCLC risk factors, such as cigarette smoking and air pollution, which result in a large patient population. Notable companies in this market include Merck KGaA, Eli Lilly and Company, Pfizer Inc., AstraZeneca, F. Hoffmann-La Roche Ltd, and Bristol-Myers Squibb Company. These companies' high-priced, effective drugs contribute to the market's high sales. Patient access to reimbursement schemes, patient assistance programs, and co-pay relief programs also facilitate increased drug sales. According to the Centers for Disease Control and Prevention (CDC), approximately 200,000 people in the US are diagnosed with lung cancer each year. The NSCLC drug market in North America includes various treatment options, such as Small Molecules (Alkylating Agents, Antimetabolites, Mitotic Inhibitors), Biologics, Multi-kinase Inhibitors, Chemotherapy, Radiation Therapy, Targeted Therapy, and Immunotherapy.

Market Dynamics

Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

What are the key market drivers leading to the rise in adoption of Non-Small Cell Lung Cancer Drugs Market ?

Increasing prevalence of NSCLC is the key driver of the market.

• The incidence of Non-Small Cell Lung Cancer (NSCLC) in North America has been on the rise, with an estimated 238,340 new cases anticipated in the US and around 30,000 diagnoses in Canada in 2023 and 2022, respectively. These statistics from the American Cancer Society and Canadian Cancer Society underscore the importance of early detection and effective treatment strategies. Diagnostic tools such as CT Scans, X-Rays, Sputum Cytology, Bronchoscopy, Thoracoscopy, and Laboratory Tests play a crucial role in identifying NSCLC in its early stages. Single Drug Therapy and Combination Therapy are common treatment approaches, with administration taking place in Hospitals and increasingly, Homecare settings.
• The significant burden of NSCLC in North America necessitates comprehensive intervention measures to address this critical health concern. Lung cancer remains the most frequently diagnosed cancer and the leading cause of cancer-related deaths in Canada, according to Statistics Canada.

What are the market trends shaping the Non-Small Cell Lung Cancer Drugs Market?

Introduction and approval of combination therapies is the upcoming trend in the market.

• Non-Small Cell Lung Cancer (NSCLC) is a leading cause of cancer-related deaths worldwide. The market for medications used in its treatment is witnessing significant growth due to the increasing number of cases and the development of new combination therapies. The rise in smoking behaviors and air pollution are key factors contributing to the increase in NSCLC cases. Daiichi Sankyo is one of the leading companies in the NSCLC drug market, with Fruquintinib (HMPL-013) being a notable medication in their pipeline. Another promising drug is the PD-L1 antibody, which is being explored for its potential in NSCLC treatment. Combination therapies are being employed to mitigate drug resistance, as tumors are less likely to develop resistance to multiple drugs.
• In January 2023, Merck KGaA received US FDA approval for KEYTRUDA, their anti-PD-1 therapy, for use in combination with platinum-containing chemotherapy as a neoadjuvant treatment for resectable NSCLC, followed by adjuvant treatment as a single agent. This approval expanded KEYTRUDA's indications in NSCLC to six, both in metastatic and earlier stages. Similarly, Novartis AG initiated the Phase III trial of the CANOPY-A study in August 2022, evaluating the efficacy of canakinumab (ACZ885), an IL-1ß inhibitor, in combination with docetaxel chemotherapy. The advancements in NSCLC drug development are expected to drive market growth, providing new treatment options for patients.

What challenges does Non-Small Cell Lung Cancer Drugs Market face during the growth?

The high cost of NSCLC treatment is a key challenge affecting the market growth.

• Non-Small Cell Lung Cancer (NSCLC) is a serious health condition that requires extensive treatment, leading to significant costs. Treatment options for NSCLC include surgery, radiation therapy, chemotherapy, targeted therapies, and immunotherapy. The cost of certain NSCLC drugs, such as vinorelbine and cisplatin, can vary greatly depending on the supply quantity. For instance, the price of vinorelbine ranges from USD 23.62 to USD 29.50 for a 1 milliliter supply and USD 45.33 to USD 84 for 5 milliliters. Similarly, cisplatin's price ranges from USD 20.69 to USD 25.43 for a 50 milliliter supply and USD 69.15 to USD 92.50 for 200 milliliters. Immunotherapy, which includes immune checkpoint inhibitors.
• These treatments are available at various outlets, including specialty clinics, hospital pharmacies, retail pharmacies, and online platforms. Cancer societies and healthcare providers play a crucial role in ensuring patients have access to these drugs. The high cost of NSCLC drugs may present a challenge to the market, but the advancements in treatment options offer hope for those diagnosed with this condition.

Exclusive Customer Landscape

The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.

 Customer Landscape

Key Companies & Market Insights

Companies are implementing various strategies, such as strategic alliances, market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

The market research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:

• AbbVie Inc.
• Amgen Inc.
• Astellas Pharma Inc.
• AstraZeneca Plc
• Bayer AG
• BeiGene Ltd.
• Boehringer Ingelheim International GmbH
• Bristol Myers Squibb Co.
• DeuterOncology NV
• Eli Lilly and Co.
• F. Hoffmann La Roche Ltd.
• Innovent Biologics Inc.
• Jiangsu Hengrui Pharmaceuticals Co. Ltd.
• Merck KGaA
• Novartis AG
• Ono Pharmaceutical Co. Ltd.
• Pfizer Inc.
• PharmaMar SA
• Regeneron Pharmaceuticals Inc.
• Sanofi SA
• Takeda Pharmaceutical Co. Ltd.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Research Analyst Overview

Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related deaths worldwide. The NSCLC drug market encompasses various treatment modalities, including chemotherapy, radiation therapy, targeted therapy, and immunotherapy. Chemotherapy utilizes small molecules such as alkylating agents, antimetabolites, and mitotic inhibitors, while biologics and multi-kinase inhibitors are employed in targeted therapy. Radiation therapy, available in forms like three-dimensional conformal radiation therapy (3D-CRT), is used in conjunction with surgery or as a standalone treatment. Immunotherapy, a burgeoning area in NSCLC treatment, employs PD-L1 antibodies and anti-TIM-3 antibodies. Oral drugs are also prevalent in the market, with companies like Novartis Pharmaceuticals, Hoffmann-La Roche, and Xcovery contributing to the pipeline.

Additionally, fruquintinib (HMPL-013) and Moderna's messenger RNA (mRNA) therapies are among the emerging treatments. NSCLC treatment expenditure is influenced by factors like smoking behaviors, air pollution, and history of asbestos or tobacco consumption. Patients receive treatments in hospitals, specialty clinics, and through homecare services. Reimbursement policies, hospital pharmacies, retail pharmacies, and online pharmacies also play a crucial role in drug accessibility. Social distancing measures have led to an increase in teleconsultations and remote monitoring, potentially impacting the market dynamics.

Request Free Sample

What are the Key Data Covered in this Market Research and Growth Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the market growth and forecasting between 2024 and 2028
• Precise estimation of the size of the market  and its contribution of the market in focus to the parent market
• Accurate predictions about upcoming market growth and trends and changes in consumer behaviour
• Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
• Thorough analysis of the market's competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the growth of market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch